16 Most Shorted Stocks Right Now
One of the most intriguing plays on the stock market is short selling. This is because it goes against conventional investment logic, which typically seeks to profit from an increase in share prices.
Fate Therapeutics Inc (FATE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 13,124,427 | $62,472,273 | +2% | 2.39% |
| 2. | D E Shaw D. E. Shaw | 4,599,439 | $21,893,330 | +56% | 0.02% |
| 3. | Citadel Investment Group Ken Griffin | 2,282,531 | $10,864,847 | +38% | 0% |
| 4. | Casdin Capital Eli Casdin | 2,050,000 | $9,758,000 | 0.85% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,817,300 | $8,650,348 | -3% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.18 | 256,639 | Large Shareholder, Director | 13,135,758 | 2023-04-21 | Filing | |
| $5.99 | 20,000 | Large Shareholder, Director | 12,879,119 | 2023-04-20 | Filing | |
| $6.00 | 25,700 | Large Shareholder, Director | 12,859,119 | 2023-04-14 | Filing | |
| $5.43 | 36,631 | Director | 282,770 | 2023-01-13 | Filing | |
| $5.67 | 88,048 | Director | 246,139 | 2023-01-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.80 | 4,718 | Officer | 119,570 | 2023-08-18 | Filing | |
| $3.71 | 632 | Director | 9,302 | 2023-08-04 | Filing | |
| $4.87 | 3,854 | Officer | 41,146 | 2023-07-05 | Filing | |
| $4.83 | 5,182 | Officer | 124,288 | 2023-07-05 | Filing | |
| $5.58 | 3,460 | Director | 9,934 | 2023-06-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,978,558 | $57,017,936 | 0% | |
| 2. | 11,723,374 | $55,803,260 | 0% | |
| 3. | 10,313,911 | $49,094,216 | 0% | |
| 4. | 4,855,779 | $23,113,508 | 0.32% | |
| 5. | 3,379,064 | $16,084,345 | 4.99% |
News See All
5 Best High Short Interest Stocks To Buy Now
n this piece, we will take a look at the five best high short interest stocks to buy now.
Fate Therapeutics, Inc. (NASDAQ:FATE) Q2 2023 Earnings Call Transcript
Operator: Welcome to the Fate Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode.
Cathie Wood is Selling These 12 Stocks in 2023
After a bruising 2022, Cathie Wood’s funds slowly started to recover this year, thanks to the broader rally in the stock market amid hopes that the Federal Reserve could pause its rate-hike spree which...
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2023 Earnings Call Transcript
Operator: Welcome to the Fate Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Hedge Fund and Insider Trading News: Seth Fischer, Ray Dalio, Jupiter Fund Management, Calculo Capital, Enphase Energy Inc (ENPH), Fate Therapeutics, Inc. (FATE), and More
Nichola Pease has quit as boss of Jupiter Fund Management for ‘personal reasons’ after just three years.
5 Best Low-Priced Growth Stocks To Buy
ADMA Biologics, Inc. (NASDAQ:ADMA) is a biotech company whose shares have shown a remarkable performance over the past 12 months, gaining about 80% in value. In March, ADMA Biologics, Inc.
Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript
Operator: Welcome to the Fate Therapeutics Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
12 Cash-Rich Small Cap Stocks To Invest In
In 2022, standard diversified portfolios suffered through their worst-performing year in a century.
Hedge Fund and Insider Trading News: Chris Hohn, Cathie Wood, ValueAct Capital, Rokos Capital Management, Brevan Howard Asset Management, DiamondHead Holdings Corp (DHHC), Appian Corporation (APPN), and More
Famed activist investor and philanthropist Chris Hohn’s fund lost money last year, breaking its streak of 13 straight profitable years as stocks tumbled.
Billionaire Hedge Funds
